Category: Life Stories
New Hope: Revolutionary Crohn’s Therapy Enters Clinical Trials
Researchers at the Hudson Institute have developed a groundbreaking therapy for perianal Crohn’s disease using extracellular vesicles that could sidestep the cost and accessibility challenges of traditional stem cell treatments. This innovative approach has entered clinical trials, offering new hope for patients with one of IBD’s most challenging manifestations.
New Hope for Perianal Crohn’s: Upadacitinib Shows Promise
New research shows upadacitinib may offer hope for perianal fistulizing Crohn’s disease, with nearly half of patients achieving clinical remission after 24 weeks. This breakthrough represents meaningful progress for those who haven’t found relief with traditional treatments.
New Entyvio Biosimilar Could Mean Big Savings for IBD Patients
A new partnership aims to bring an Entyvio biosimilar to market, potentially offering IBD patients more affordable access to this important treatment. Here’s what this development could mean for our community and your treatment options.
The Surprising Link Between Crohn’s and Asthma: What You Need to Know
New research reveals a significant link between Crohn’s disease and asthma, with people living with Crohn’s showing higher rates of respiratory symptoms. This connection appears to be rooted in shared inflammatory pathways that affect both the gut and lungs.
New Hope for Kids with IBD: Oral Vancomycin Shows Promise
Recent research shows promising results for children with IBD treated with oral vancomycin, with significant improvements in symptoms and disease markers. While preliminary, this study offers hope for families seeking new treatment approaches for pediatric IBD.
Chris’s Crohn’s Journey: Breaking Silence Around Invisible Illness
Chris Evans from Aberdeen shares his decade-long journey with Crohn’s disease, from initial misdiagnosis to surgery and ongoing management. His story highlights the challenges of living with an invisible illness while advocating for greater awareness and reduced stigma in the IBD community.
New Crohn’s Drug Shows Promise: What Mirikizumab Could Mean
New clinical trial results show mirikizumab helped over half of treatment-resistant Crohn’s patients achieve remission, with participants reporting improved quality of life and restored energy. This experimental drug represents promising progress in targeted IBD therapy.
New Crohn’s Treatment Shows Promise: What Obefazimod Could Mean
New research on obefazimod shows promising results for people with moderate to severe Crohn’s disease, with encouraging rates of clinical remission and improved quality of life. While still in clinical trials, this development offers hope for better treatment options ahead.
Ultraprocessed Grains May Increase IBD Risk: Research Findings
New European research following over 100,000 adults found that high consumption of ultraprocessed grains may increase IBD risk. This finding remained significant even after accounting for other dietary and lifestyle factors, offering important insights for the IBD community about food processing and gut health.
New Research on Gut Chemical Succinate Could Change Crohn’s Treatment
New research reveals that succinate, a naturally occurring gut chemical, may drive inflammation in Crohn’s disease. This discovery could lead to targeted treatments that rebalance gut chemistry rather than broadly suppressing the immune system.
